… ProQR Announces Second Quarter 2021 Operating and Financial … & CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … eye disease,” said Daniel A. de Boer, Founder and CEO of ProQR. “We completed enrollment in the pivotal trial of …
… ProQR Announces Upcoming Investor Conferences in April and … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … will be accessible from the “Investors & Media” section of ProQR’s website under “ Events ”. Archived webcasts will be …
… ProQR Announces Upcoming Investor Conferences in November and … & CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … will be accessible from the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under “ Events ”. Archived …
… ProQR Announces Results for the Third Quarter of 2017 Key … Scott Armstrong and Thaddeus (Ted) Dryja appointed to ProQR’s Scientific Advisory Board (SAB). In vivo proof of … Questionnaire-Revised Respiratory Symptom Score, or CFQ-R RSS) compared to placebo. A supportive trend was observed …
Illuminate Phase 2/3 trial of sepofarsen expected to complete enrollment in Q1 2021; additional data from Phase 1/2 InSight extension study to be reported in H2 2021
Enrollment completed for QR-421a dosing cohorts and data from next Phase 1/2 interim
Positive preliminary data from InSight extension study of sepofarsen for LCA10 reported – consistent with benefit seen in Phase 1/2 and building confidence in Phase 2/3 Illuminate trial;
Strategic convertible debt financing extends runway into 2023 if fully draw
Reported positive interim analysis findings from Phase 1/2 Stellar trial of QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa – study ongoing with dose expansion and escalation planned;Updated data from the Phase 1/2 InSight extension st